Key facts
- This page summarizes Robert Lisicki's Form 3 filing for Arcutis Biotherapeutics, Inc. (ARQT).
- 0 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 04 Nov 2026, 18:38.
Key filing fact
Ownership activity is grounded in SEC Form 3 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
No transaction description listed
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
No transaction description listed
Additional SEC filing notes
Footnote F1
Represents restricted stock units ("RSUs") that will vest as of 25% of the RSUs on each annual anniversary of August 17, 2026 (the "Vesting Commencement Date"), beginning on August 17, 2027, subject to the Reporting Person's continued service through the vesting date.
Footnote F2
The options will vest and become exercisable at the rate of 2.0833% of the shares on each monthly anniversary of August 17, 2026, (the "Vesting Commencement Date"), subject to the Reporting Person's continued service through the applicable vesting date.
SEC remarks
Exhibit List: EX-24 - Power of Attorney.